Last reviewed · How we verify
NCT06344611
Incidence & Predictive Factors of Recompensation in Children With Decompensated Cirrhosis as Per the Baveno VII Criteria
trial testing Other in Decompensated Cirrhosis in 50 participants. Status unknown.
31 March 2026
Quick facts
| Lead sponsor | Institute of Liver and Biliary Sciences, India |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 7 April 2024 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 March 2026 |
| Sites | 1 location across India |
Drugs / interventions tested
- Other
Conditions studied
- Decompensated Cirrhosis — all drugs for Decompensated Cirrhosis →
Sponsor
Institute of Liver and Biliary Sciences, India
Who can join
Adults 3 Months to 18, any sex, with Decompensated Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cirrhosis is a leading cause of morbidity and mortality world- wide and can develop on the basis of repetitive and/or chronic liver injury due to toxic, infectious, metabolic and genetic pathogenic factors. Traditionally, the natural history of cirrhosis has often been considered a one-way street, with a definite and irreversible progression from a compensated to a decompensated disease stage. But recent data has shown that if the underlying etiology can be successfully treated, cirrhosis can regress and recompensation of liver disease can occur. Hence, in this study we want to evaluate the incidence and predictive factors of recompensation in pediatric subjects with decompensated cirrhosis as per the Baveno VII criteria. We would also evaluate the predictive factors of recompensation in pediatric decompensated chronic liver disase (DCLD) subjects and would explore systemic and intestinal inflammatory markers as possible biomarkers for predicting recompensation in pediatric subjects with decompensated cirrhosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06344611
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Other
Trials testing the same drug.
- NCT07118163 — The Relationship Pain Beliefs With Kinesiophobia, Catastrophizing, Pain Knowledge, and Shoulder Functional Disability in · not yet recruiting
- NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
- NCT06802237 — Development and Standardization Methods · completed
- NCT06091475 — Therapy to Maintain Remission in Dilated Cardiomyopathy · NA · recruiting
- NCT06026488 — Real-World Study of DLBCL With Different Genetic Subtypes · recruiting
Other recruiting trials for Decompensated Cirrhosis
Currently open trials in the same condition.
- NCT06823713 — RTX001 Autologous Engineered Macrophages for Liver Cirrhosis · Phase 1, PHASE2 · recruiting
- NCT05224960 — Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2) · Phase 2 · recruiting
- NCT06396897 — Hospital @ Home Model of Care for Cirrhosis · NA · recruiting
- NCT06374511 — Prospective Cohort Study of Complications and Outcomes in Cirrhosis · recruiting
- NCT06134544 — Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis · NA · recruiting
Other Institute of Liver and Biliary Sciences, India trials
Trials by the same sponsor.
- NCT07480005 — To Revisit the Yield of Staging Laparoscopy in Hepatopancreatobiliary Malignancies · recruiting
- NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
- NCT07465471 — Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. · NA · not yet recruiting
- NCT07433881 — Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis · not yet recruiting
- NCT07422948 — Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06344611 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Liver and Biliary Sciences, India
- Last refreshed: 3 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06344611.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing